215 related articles for article (PubMed ID: 31218960)
1. STAT3: A Potential Drug Target for Tumor and Inflammation.
Hu YS; Han X; Liu XH
Curr Top Med Chem; 2019; 19(15):1305-1317. PubMed ID: 31218960
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of STAT3 for cancer therapy.
Zhao M; Jiang B; Gao FH
Curr Med Chem; 2011; 18(26):4012-8. PubMed ID: 21824090
[TBL] [Abstract][Full Text] [Related]
3. Recent Update on Development of Small-Molecule STAT3 Inhibitors for Cancer Therapy: From Phosphorylation Inhibition to Protein Degradation.
Dong J; Cheng XD; Zhang WD; Qin JJ
J Med Chem; 2021 Jul; 64(13):8884-8915. PubMed ID: 34170703
[TBL] [Abstract][Full Text] [Related]
4. Strategies and Approaches of Targeting STAT3 for Cancer Treatment.
Furtek SL; Backos DS; Matheson CJ; Reigan P
ACS Chem Biol; 2016 Feb; 11(2):308-18. PubMed ID: 26730496
[TBL] [Abstract][Full Text] [Related]
5. Identification of STAT1 and STAT3 specific inhibitors using comparative virtual screening and docking validation.
Szelag M; Czerwoniec A; Wesoly J; Bluyssen HA
PLoS One; 2015; 10(2):e0116688. PubMed ID: 25710482
[TBL] [Abstract][Full Text] [Related]
6. Targeting transcription factor STAT3 for cancer prevention and therapy.
Chai EZ; Shanmugam MK; Arfuso F; Dharmarajan A; Wang C; Kumar AP; Samy RP; Lim LH; Wang L; Goh BC; Ahn KS; Hui KM; Sethi G
Pharmacol Ther; 2016 Jun; 162():86-97. PubMed ID: 26478441
[TBL] [Abstract][Full Text] [Related]
7. Signal Transducer and Activator of Transcription Protein 3 (STAT3): An Update on its Direct Inhibitors as Promising Anticancer Agents.
Gelain A; Mori M; Meneghetti F; Villa S
Curr Med Chem; 2019; 26(27):5165-5206. PubMed ID: 30027840
[TBL] [Abstract][Full Text] [Related]
8. Novel activators and small-molecule inhibitors of STAT3 in cancer.
Yang L; Lin S; Xu L; Lin J; Zhao C; Huang X
Cytokine Growth Factor Rev; 2019 Oct; 49():10-22. PubMed ID: 31677966
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel small molecules that inhibit STAT3-dependent transcription and function.
Kolosenko I; Yu Y; Busker S; Dyczynski M; Liu J; Haraldsson M; Palm Apergi C; Helleday T; Tamm KP; Page BDG; Grander D
PLoS One; 2017; 12(6):e0178844. PubMed ID: 28636670
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of small molecule inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Ding N; Zhang W; Li Y
Bioorg Med Chem Lett; 2013 Apr; 23(7):2225-9. PubMed ID: 23434226
[TBL] [Abstract][Full Text] [Related]
11. Highlighted STAT3 as a potential drug target for cancer therapy.
Lee H; Jeong AJ; Ye SK
BMB Rep; 2019 Jul; 52(7):415-423. PubMed ID: 31186087
[TBL] [Abstract][Full Text] [Related]
12. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
Huang W; Liu Y; Wang J; Yuan X; Jin HW; Zhang LR; Zhang JT; Liu ZM; Cui JR
Eur J Med Chem; 2018 Sep; 157():887-897. PubMed ID: 30145375
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel inhibitors of signal transducer and activator of transcription 3 (STAT3) signaling pathway by virtual screening.
Zhang M; Zhu W; Li Y
Eur J Med Chem; 2013 Apr; 62():301-10. PubMed ID: 23376248
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting signal transducer and activator of transcription 3: rationality and rationale design of inhibitors.
Mankan AK; Greten FR
Expert Opin Investig Drugs; 2011 Sep; 20(9):1263-75. PubMed ID: 21751940
[TBL] [Abstract][Full Text] [Related]
15. N-Arylsulfonylsubstituted-1H indole derivatives as small molecule dual inhibitors of signal transducer and activator of transcription 3 (STAT3) and tubulin.
Zhou Q; Zhu J; Chen J; Ji P; Qiao C
Bioorg Med Chem; 2018 Jan; 26(1):96-106. PubMed ID: 29174507
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and biological evaluation of new N-alkylcarbazole derivatives as STAT3 inhibitors: preliminary study.
Saturnino C; Palladino C; Napoli M; Sinicropi MS; Botta A; Sala M; Carcereri de Prati A; Novellino E; Suzuki H
Eur J Med Chem; 2013 Feb; 60():112-9. PubMed ID: 23287056
[TBL] [Abstract][Full Text] [Related]
17. STAT3 and metabolism: how many ways to use a single molecule?
Demaria M; Camporeale A; Poli V
Int J Cancer; 2014 Nov; 135(9):1997-2003. PubMed ID: 24500994
[TBL] [Abstract][Full Text] [Related]
18. Identification of Lead Compounds as Inhibitors of STAT3: Design, Synthesis and Bioactivity.
Botta A; Sirignano E; Popolo A; Saturnino C; Terracciano S; Foglia A; Sinicropi MS; Longo P; Di Micco S
Mol Inform; 2015 Oct; 34(10):689-97. PubMed ID: 27490969
[TBL] [Abstract][Full Text] [Related]
19. Two decades of research in discovery of anticancer drugs targeting STAT3, how close are we?
Beebe JD; Liu JY; Zhang JT
Pharmacol Ther; 2018 Nov; 191():74-91. PubMed ID: 29933035
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting aberrant Stat3 function with molecular therapeutics: a progress report.
Haftchenary S; Avadisian M; Gunning PT
Anticancer Drugs; 2011 Feb; 22(2):115-27. PubMed ID: 21063201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
